UNCY NASDAQ
Unicycive Therapeutics, Inc.
1W: -5.0%
1M: -22.2%
3M: -23.8%
YTD: -37.8%
1Y: -29.6%
3Y: -58.5%
5Y: -85.8%
$3.61
+0.03 (+0.84%)
Weekly Expected Move ±8.7%
$3
$4
$4
$4
$5
Credit Risk of going bust: lower than 62% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.9M.
Distance to default 6.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.4%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.9M.
Distance to default 6.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.4%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$0M
Revenue
+0.0% YoY
$-35M
Net Income
-11.8% YoY
$-28M
Free Cash Flow
+16.1% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-101.1%
ROA-69.1%
ROIC349.9%
Valuation
P/E-2.2
P/B1.8
EV/EBITDA-1.9
Leverage
Debt/Equity0.01
Current Ratio3.81
Interest Cov.-837.7x
Quality Scores
Piotroski F4/9
Altman Z0.54
Beneish M0.00